New 'Off-the-Shelf' cell therapy tested in patients with Hard-to-Treat blood cancers

NCT ID NCT04984356

Completed Disease control Sponsor: Wugen, Inc. Source: ClinicalTrials.gov ↗

Summary

This study tested the safety and early effectiveness of a new type of CAR-T cell therapy called WU-CART-007 in adults and adolescents with T-cell leukemia or lymphoma that has returned or not responded to previous treatments. The therapy uses genetically modified immune cells from a donor (not the patient) to target and attack cancer cells. Researchers aimed to find the safest and most effective dose for future studies.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Children's Hospital Los Angeles

Los Angeles, California, 90027, United States
Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
City of Hope

Duarte, California, 91010, United States
Erasmus MC

Rotterdam, Netherlands
Hospital Saint- Louis

Paris, France
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Peter MacCallum Cancer Centre

Melbourne, Victoria, Australia
Prinses Maxima Centrum

Utrecht, Netherlands
University Hospital Robert Debre

Paris, France
University of Wisconsin

Madison, Wisconsin, 53792, United States
Vanderbilt University

Nashville, Tennessee, 37212, United States
Washington University

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

LYMPHOBLASTIC LYMPHOMA T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA